Allurion Technologies Stock Soars Following Clinical Study Announcement
Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% after the company announced its plans to initiate a clinical study focused on optimizing muscle mass during GLP-1 therapy in combination with the Allurion Program. This significant rise in the company’s stock price is attributed to the promising potential of the Allurion Program to address the loss of lean mass commonly seen with GLP-1 therapy, a recurrent issue in obesity treatment. According to the press release, prior studies have shown that patients on GLP-1 therapy tend to lose about 40% of their lean mass as a proportion of total weight lost. In contrast, patients treated with the Allurion Balloon and Allurion Virtual Care Suite have not only lost weight but have also maintained or even gained lean body mass. The CEO of Allurion, Dr. Shantanu Gaur, expressed optimism about the upcoming clinical study, stating that the company’s early data suggests they may have a significant tool for achieving metabolically he...